Loading
Natures Sunshine Products Inc Stock: price and insider trades · United States
1 insider bought €2.3M of shares over the last 90 days, the latest filed 19 Aug 2026.
Natures Sunshine Products Inc: what insiders have been doing
Every trade that managers of Natures Sunshine Products Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Lehi, United States. It was founded in 1972. 12 insiders have disclosed 65 filings since 18 October 2025.
The record shows 14 purchases on the open market worth €2.3M, made by 1 insider, against 8 sales worth €1.4M by 4 insiders. The net balance comes to €867k on the buying side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. On the buying side, the filings list 1 major shareholder among the declarants. The largest single trade was a purchase of €434k by Prescott Group Capital Management, L.L.C., published on 10 August 2026, equal to 0.22% of the market capitalisation.
Across the 5,813 companies tracked on its exchange, the median is 19 filings; at 65 filings, this issuer sits above that mark. Since 2016, the database holds 20 purchases and 20 sales by insiders of the company. The 10-K for the year ended 31 December 2025 shows 480.1 m USD of revenue and 19.5 m USD of net income.
The last purchase on record was published on 19 August 2026, which is 60 days ago. Typically, a trade is published a median of 3 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
267
Thresholds
n/a
Buy Volume
€2M
20 ops. · all time
Sell Volume
€30M
20 ops. · all time
Who traded when
BuySalePrescott Group Capital Management, L.L.C.14 buys
Bryant J. Yates3 sales
Jonathan David Lanoy3 sales
Nathan G. Brower3 sales
Daniel C. Norman2 sales
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.1 sale
Since the insiders bought
- -11.7%Entry US$14.32 · Close 16 Oct 2026 US$12.64
- +78.8%Entry US$9.00 · Close at T+365 US$16.09
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 1,405 of 24,148 companies
77.9
score / 100
Value86
Quality70
FCF yld13%
Earn yld8.8%
EV/EBITDA5.5x
ROE11%
Gross mgn72%
Net mgn4.1%
Debt/EBITDA0.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$12.61
Analyst consensus
2 analysts1.00/5
US$25.00Target US$30.50(+142%)US$36.00
Income statement
RevenueUS$480.1M
Gross profitUS$347.7M72% margin
EBITDAUS$43.8M9% margin
Net incomeUS$19.5M3.7% margin
Valuation
PER (trailing)12.6x
PER (forward)10.3x
P/Book1.3x
Beta0.81
Balance sheet & cash
Market capUS$221.9M
Total debtUS$18.9M
Free Cash FlowUS$28.8M
Debt / Equity13%
Profitability & ownership
ROE11.2%
ROA7.1%
% insiders3.5%
% institutions92.6%
Last declaration on 15 September 2026
Declarations267 total
36,049 shares0Common SharesSEC:0001628280-26-062046:1
39,384 shares0Common SharesSEC:0001628280-26-062046:0
7,210 shares0Common SharesSEC:0001628280-26-060339:0
20,000 shares@ US$14.690.13% mcap11.2% of flowCommon Stock, no par valueSEC:0001166152-26-000011:0
Canonical exit: 15 Nov 2026 (T+90)
1,000 shares@ US$16.480.0071% mcap0.6% of flowCommon Stock, no par valueSEC:0001166152-26-000010:3
Canonical exit: 5 Nov 2026 (T+90)
20,000 shares@ US$16.690.14% mcap12.8% of flowCommon Stock, no par valueSEC:0001166152-26-000010:7
Canonical exit: 5 Nov 2026 (T+90)
10,000 shares@ US$16.720.072% mcap6.4% of flowCommon Stock, no par valueSEC:0001166152-26-000010:8
Canonical exit: 5 Nov 2026 (T+90)
876 shares@ US$15.640.0059% mcap0.5% of flowCommon Stock, no par valueSEC:0001166152-26-000010:9
Canonical exit: 8 Nov 2026 (T+90)
16,928 shares@ US$15.800.12% mcap10.2% of flowCommon Stock, no par valueSEC:0001166152-26-000010:10
Canonical exit: 8 Nov 2026 (T+90)
13,072 shares@ US$15.780.089% mcap7.9% of flowCommon Stock, no par valueSEC:0001166152-26-000010:11
Canonical exit: 8 Nov 2026 (T+90)
10,000 shares@ US$16.010.069% mcap6.1% of flowCommon Stock, no par valueSEC:0001166152-26-000010:12
Canonical exit: 8 Nov 2026 (T+90)
2,000 shares@ US$16.350.014% mcap1.2% of flowCommon Stock, no par valueSEC:0001166152-26-000010:0
Canonical exit: 4 Nov 2026 (T+90)
2,513 shares@ US$16.750.018% mcap1.6% of flowCommon Stock, no par valueSEC:0001166152-26-000010:1
Canonical exit: 4 Nov 2026 (T+90)
10,000 shares@ US$16.460.071% mcap6.3% of flowCommon Stock, no par valueSEC:0001166152-26-000010:2
Canonical exit: 5 Nov 2026 (T+90)
20,000 shares@ US$16.550.14% mcap12.7% of flowCommon Stock, no par valueSEC:0001166152-26-000010:4
Canonical exit: 5 Nov 2026 (T+90)
5,000 shares@ US$16.620.036% mcap3.2% of flowCommon Stock, no par valueSEC:0001166152-26-000010:5
Canonical exit: 5 Nov 2026 (T+90)
30,000 shares@ US$16.680.22% mcap19.2% of flowCommon Stock, no par valueSEC:0001166152-26-000010:6
Canonical exit: 5 Nov 2026 (T+90)
1,976 sharesCommon SharesSEC:0001628280-26-045913:0
12,015 shares@ US$21.840.10% mcap22.8% of flowCommon SharesSEC:0001628280-26-037603:0
3,512 shares@ US$27.070.037% mcap11.6% of flowCommon SharesSEC:0001628280-26-026367:0
1,289 shares@ US$27.070.013% mcap3.0% of flowCommon SharesSEC:0001628280-26-026369:0
951 shares@ US$27.070.0099% mcap4.2% of flowCommon SharesSEC:0001628280-26-026365:0
1,567 shares@ US$27.070.016% mcap3.1% of flowCommon SharesSEC:0001628280-26-026361:0
1,567 shares@ US$27.070.016% mcap3.5% of flowCommon SharesSEC:0001628280-26-026363:0
11,798 sharesCommon SharesSEC:0001628280-26-021359:0
25 of 267 declarations
About Natures Sunshine Products Inc
Nature’s Sunshine Products, Inc. (Nasdaq: NATR) is a United States-listed company trading on the NASDAQ market in the United States. Headquartered in Lehi, Utah, the company is a long-established player in the natural health and wellness space, with a history spanning more than 50 years. Its core business is the formulation, manufacturing and marketing of herbal supplements, nutritional products and selected personal care items, with a brand identity centered on natural ingredients, product quality and wellness-oriented routines. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000275053/000162828026016535/natrq42025earningsrelease.htm))
From an industry perspective, Nature’s Sunshine sits in the competitive mid-cap consumer health niche where brand trust, ingredient sourcing, regulatory discipline and product innovation are critical. The company emphasizes that it manufactures most of its products through its own facilities, giving it tighter control over quality, safety and efficacy. It also distributes in more than 40 countries worldwide, which provides meaningful geographic diversification and reduces reliance on any single market. That international footprint is particularly relevant for investors looking at a US-based wellness business with a global reach. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000275053/000162828026016535/natrq42025earningsrelease.htm))
Read moreShow less
The product portfolio includes herbal and nutritional supplements, everyday wellness formulas, and category-specific lines aimed at digestion, vitality, metabolic support and general health maintenance. In 2025, Nature’s Sunshine relaunched its Power Line with a new Power Balance supplement, signaling active portfolio management and a willingness to refresh its offering around consumer health trends. The company also introduced its first integrated brand platform, “Be More Earth,” which reinforces its natural positioning and underscores the role of ingredient authenticity in its marketing strategy. ([ir.naturessunshine.com](https://ir.naturessunshine.com/news-events/press-releases/detail/260/natures-sunshine-relaunches-revolutionary-power-line-to))
Recent developments point to a more constructive operating backdrop. Through late 2025 and early 2026, the company reported stronger financial performance, lifted guidance, and highlighted improving sales momentum and margin trends. It also continued repurchasing shares while maintaining a solid balance sheet profile, including cash and no debt at year-end 2025 according to its financial communications. For investors, NATR can be viewed as a US natural-health consumer company with international distribution, in-house manufacturing capabilities and a recent operational recovery that may improve its investment case if execution remains consistent. ([ir.naturessunshine.com](https://ir.naturessunshine.com/news-events/press-releases/detail/267/natures-sunshine-reports-strong-fourth-quarter-and-full/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
